Last 12 months
Inside the activity.
0 purchase rows · 35 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 16 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 17 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 03, 2023 Filed May 5, 2023 21:19 UTC |
MIZELL STEVENEVP, Chief HR Officer
|
Exercise / conversionCommon Stock | 15,000 | $75.36 | $1,130,400.00 |
DisclosureSEC source: 0001127602-23-014764 · form4.xml · nonDerivative · entry 2 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,085.145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercise and sale transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2023. Read SEC document |
| May 03, 2023 Filed May 5, 2023 21:19 UTC |
MIZELL STEVENEVP, Chief HR Officer
|
Exercise / conversionCommon Stock | 13,000 | $77.62 | $1,009,060.00 |
DisclosureSEC source: 0001127602-23-014764 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,085.145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercise and sale transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2023. Read SEC document |
| May 02, 2023 Filed May 3, 2023 20:29 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,035 | $0.00 Strike: $56.04 | $0.00 |
DisclosureSEC source: 0001127602-23-014278 · form4.xml · derivative · entry 6 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,035 shares Expires 2028-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2019, 5/4/2020, and 5/4/2021. Read SEC document |
| May 02, 2023 Filed May 3, 2023 20:29 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
SaleCommon Stock | 7,509 | $116.82 | $877,222.41 |
DisclosureSEC source: 0001127602-23-014278 · form4.xml · nonDerivative · entry 4 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,058.96 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.7200 to $116.8800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| May 02, 2023 Filed May 3, 2023 20:29 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
Exercise / conversionCommon Stock | 6,035 | $56.04 | $338,201.40 |
DisclosureSEC source: 0001127602-23-014278 · form4.xml · nonDerivative · entry 3 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,567.96 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2023 Filed May 4, 2023 21:34 UTC |
Zachary JenniferEVP, General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 41,494 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014537 · form4.xml · derivative · entry 2 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,494 Underlying: Common Stock · 41,494 shares Expires 2033-05-01 F2 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 21:40 UTC |
MIZELL STEVENEVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 29,046 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014539 · form4.xml · derivative · entry 2 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,046 Underlying: Common Stock · 29,046 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 21:43 UTC |
Guindo ChirfiChief Marketing Officer
|
GrantStock Option (Right to Buy) · Derivative | 34,578 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014541 · form4.xml · derivative · entry 3 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,578 Underlying: Common Stock · 34,578 shares Expires 2033-05-01 F3 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 21:47 UTC |
Downing Cristal NChief Comm. & Public Afrs Ofcr
|
GrantStock Option (Right to Buy) · Derivative | 17,981 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014543 · form4.xml · derivative · entry 1 Downing Cristal N · CIK 0001879216 · Chief Comm. & Public Afrs Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,981 Underlying: Common Stock · 17,981 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 21:50 UTC |
Romanelli JosephPresident, Human Health Int?l
|
GrantRestricted Stock Unit · Derivative | 6,786 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014547 · form4.xml · derivative · entry 3 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,786 Underlying: Common Stock · 6,786 shares Expires 2026-05-02 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 21:50 UTC |
Romanelli JosephPresident, Human Health Int?l
|
GrantStock Option (Right to Buy) · Derivative | 23,513 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014547 · form4.xml · derivative · entry 2 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,513 Underlying: Common Stock · 23,513 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 21:56 UTC |
Li Dean YExecutive VP & President, MRL
|
GrantStock Option (Right to Buy) · Derivative | 77,455 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014553 · form4.xml · derivative · entry 2 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,455 Underlying: Common Stock · 77,455 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:01 UTC |
Oosthuizen Johannes JacobusPresident, U.S. Market
|
GrantStock Option (Right to Buy) · Derivative | 20,747 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014557 · form4.xml · derivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,747 Underlying: Common Stock · 20,747 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:11 UTC |
Davis Robert MDirector · Chairman, CEO & President
|
GrantStock Option (Right to Buy) · Derivative | 186,722 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014561 · form4.xml · derivative · entry 2 Davis Robert M · CIK 0001363076 · Director · Chairman, CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,722 Underlying: Common Stock · 186,722 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:14 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Heallth
|
GrantStock Option (Right to Buy) · Derivative | 44,260 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014564 · form4.xml · derivative · entry 3 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,260 Underlying: Common Stock · 44,260 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:18 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
GrantStock Option (Right to Buy) · Derivative | 45,643 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014567 · form4.xml · derivative · entry 5 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,643 Underlying: Common Stock · 45,643 shares Expires 2033-05-01 F4 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:22 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
GrantStock Option (Right to Buy) · Derivative | 19,364 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014569 · form4.xml · derivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,364 Underlying: Common Stock · 19,364 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:26 UTC |
Klobuchar Michael AEVP - Chief Strategy Officer
|
GrantStock Option (Right to Buy) · Derivative | 20,747 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014571 · form4.xml · derivative · entry 6 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,747 Underlying: Common Stock · 20,747 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:29 UTC |
Litchfield CarolineEVP & CFO
|
GrantStock Option (Right to Buy) · Derivative | 58,783 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014574 · form4.xml · derivative · entry 2 Litchfield Caroline · CIK 0001854928 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,783 Underlying: Common Stock · 58,783 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:33 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
GrantRestricted Stock Unit · Derivative | 1,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014578 · form4.xml · derivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,781 Underlying: Common Stock · 1,781 shares Expires 2026-05-02 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:33 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
GrantStock Option (Right to Buy) · Derivative | 9,682 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014578 · form4.xml · derivative · entry 2 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,682 Underlying: Common Stock · 9,682 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:37 UTC |
LeCointe-Cephas LisaSVP Chief Ethics & Com Officer
|
GrantRestricted Stock Unit · Derivative | 1,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014583 · form4.xml · derivative · entry 3 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,781 Underlying: Common Stock · 1,781 shares Expires 2026-05-02 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:37 UTC |
LeCointe-Cephas LisaSVP Chief Ethics & Com Officer
|
GrantStock Option (Right to Buy) · Derivative | 9,682 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014583 · form4.xml · derivative · entry 2 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,682 Underlying: Common Stock · 9,682 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 01, 2023 Filed May 2, 2023 15:37 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Heallth
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 75,436 | $0.00 Strike: $56.04 | $0.00 |
DisclosureSEC source: 0001127602-23-014025 · form4.xml · derivative · entry 7 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,436 shares Expires 2028-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F8 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2019, 5/4/2020, and 5/4/2021. Read SEC document |
| May 01, 2023 Filed May 2, 2023 15:37 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Heallth
|
SaleCommon Stock | 75,436 | $116.03 | $8,752,748.56 |
DisclosureSEC source: 0001127602-23-014025 · form4.xml · nonDerivative · entry 4 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,492.854 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.0000 to $116.1400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2023 Filed May 2, 2023 15:37 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Heallth
|
Exercise / conversionCommon Stock | 75,436 | $56.04 | $4,227,433.44 |
DisclosureSEC source: 0001127602-23-014025 · form4.xml · nonDerivative · entry 3 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,928.854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:00 UTC |
Klobuchar Michael AEVP - Chief Strategy Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014204 · form4.xml · derivative · entry 7 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 866 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:00 UTC |
Klobuchar Michael AEVP - Chief Strategy Officer
|
Tax withholdingCommon Stock | 427 | $115.47 | $49,305.69 |
DisclosureSEC source: 0001127602-23-014204 · form4.xml · nonDerivative · entry 4 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,590.999 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:00 UTC |
Klobuchar Michael AEVP - Chief Strategy Officer
|
Exercise / conversionCommon Stock | 866 | $115.47 | $99,997.02 |
DisclosureSEC source: 0001127602-23-014204 · form4.xml · nonDerivative · entry 3 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,901.461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:11 UTC |
LeCointe-Cephas LisaSVP Chief Ethics & Com Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 643 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014206 · form4.xml · derivative · entry 3 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 643 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:11 UTC |
LeCointe-Cephas LisaSVP Chief Ethics & Com Officer
|
Tax withholdingCommon Stock | 221 | $115.47 | $25,518.87 |
DisclosureSEC source: 0001127602-23-014206 · form4.xml · nonDerivative · entry 2 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,154.693 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:11 UTC |
LeCointe-Cephas LisaSVP Chief Ethics & Com Officer
|
Exercise / conversionCommon Stock | 643 | $115.47 | $74,247.21 |
DisclosureSEC source: 0001127602-23-014206 · form4.xml · nonDerivative · entry 1 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,375.693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:54 UTC |
Oosthuizen Johannes JacobusPresident, U.S. Market
|
Exercise / conversionRestricted Stock Unit · Derivative | 866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014222 · form4.xml · derivative · entry 3 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 866 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:54 UTC |
Oosthuizen Johannes JacobusPresident, U.S. Market
|
Tax withholdingCommon Stock | 427 | $115.47 | $49,305.69 |
DisclosureSEC source: 0001127602-23-014222 · form4.xml · nonDerivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,299.748 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:54 UTC |
Oosthuizen Johannes JacobusPresident, U.S. Market
|
Exercise / conversionCommon Stock | 866 | $115.47 | $99,997.02 |
DisclosureSEC source: 0001127602-23-014222 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,726.748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:07 UTC |
Litchfield CarolineEVP & CFO
|
Exercise / conversionRestricted Stock Unit · Derivative | 866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014238 · form4.xml · derivative · entry 3 Litchfield Caroline · CIK 0001854928 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 866 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:07 UTC |
Litchfield CarolineEVP & CFO
|
Tax withholdingCommon Stock | 427 | $115.47 | $49,305.69 |
DisclosureSEC source: 0001127602-23-014238 · form4.xml · nonDerivative · entry 2 Litchfield Caroline · CIK 0001854928 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,691.269 Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:07 UTC |
Litchfield CarolineEVP & CFO
|
Exercise / conversionCommon Stock | 866 | $115.47 | $99,997.02 |
DisclosureSEC source: 0001127602-23-014238 · form4.xml · nonDerivative · entry 1 Litchfield Caroline · CIK 0001854928 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,118.269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:10 UTC |
Li Dean YExecutive VP & President, MRL
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014248 · form4.xml · derivative · entry 3 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,062 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:10 UTC |
Li Dean YExecutive VP & President, MRL
|
Tax withholdingCommon Stock | 524 | $115.47 | $60,506.28 |
DisclosureSEC source: 0001127602-23-014248 · form4.xml · nonDerivative · entry 2 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,471.432 Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:10 UTC |
Li Dean YExecutive VP & President, MRL
|
Exercise / conversionCommon Stock | 1,062 | $115.47 | $122,629.14 |
DisclosureSEC source: 0001127602-23-014248 · form4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,995.432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:24 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
Exercise / conversionRestricted Stock Unit · Derivative | 930 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014272 · form4.xml · derivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 930 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:24 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
Tax withholdingCommon Stock | 319 | $115.47 | $36,834.93 |
DisclosureSEC source: 0001127602-23-014272 · form4.xml · nonDerivative · entry 2 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,559.972 Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:24 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
Exercise / conversionCommon Stock | 930 | $115.47 | $107,387.10 |
DisclosureSEC source: 0001127602-23-014272 · form4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,878.972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:29 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 577 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014278 · form4.xml · derivative · entry 5 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 577 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:29 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
Tax withholdingCommon Stock | 198 | $115.47 | $22,863.06 |
DisclosureSEC source: 0001127602-23-014278 · form4.xml · nonDerivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,532.96 Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:29 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
Exercise / conversionCommon Stock | 577 | $115.47 | $66,626.19 |
DisclosureSEC source: 0001127602-23-014278 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,730.96 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| April 28, 2023 Filed Apr 28, 2023 21:15 UTC |
Davis Robert MDirector · Chairman, CEO & President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 143,329 | $0.00 Strike: $56.04 | $0.00 |
DisclosureSEC source: 0001127602-23-013808 · form4.xml · derivative · entry 3 Davis Robert M · CIK 0001363076 · Director · Chairman, CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 143,329 shares Expires 2028-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F3 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2019, 5/4/2020, and 5/4/2021. Read SEC document |
| April 28, 2023 Filed Apr 28, 2023 21:15 UTC |
Davis Robert MDirector · Chairman, CEO & President
|
SaleCommon Stock | 143,329 | $114.93 | $16,472,844.97 |
DisclosureSEC source: 0001127602-23-013808 · form4.xml · nonDerivative · entry 2 Davis Robert M · CIK 0001363076 · Director · Chairman, CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,816.757 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.5200 to $115.3300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| April 28, 2023 Filed Apr 28, 2023 21:15 UTC |
Davis Robert MDirector · Chairman, CEO & President
|
Exercise / conversionCommon Stock | 143,329 | $56.04 | $8,032,157.16 |
DisclosureSEC source: 0001127602-23-013808 · form4.xml · nonDerivative · entry 1 Davis Robert M · CIK 0001363076 · Director · Chairman, CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 415,145.757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.